Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA®▼ (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
- EMEA Innovative Medicine
- Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA®▼ (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
Janssen Presents Study Results Showing Clinical Efficacy for TREMFYA®▼ (guselkumab) and Long-Term Safety Profile for STELARA® (ustekinumab) for Patients Living with Inflammatory Bowel Disease at Digestive Disease Week® 2022
- X (Twitter)
Copy link